Masaya Ono

National Cancer Research Institute

Papers

1

Total Citations

35

H-Index

1

About

Masaya Ono is a leading figure in clinical proteomics and cancer biomarker discovery, with a particular focus on improving treatment outcomes for pancreatic cancer. His most cited work, a 2010 study on survival prediction for pancreatic cancer patients receiving gemcitabine, exemplifies his commitment to addressing a critical clinical challenge: the wide variability in patient response to standard chemotherapy. By employing liquid chromatography-mass spectrometry (LC-MS) to analyze baseline protein profiles, Ono pioneered a method to identify predictive biomarkers, aiming to spare non-responders from ineffective treatment. This foundational study, with 35 citations, has influenced subsequent efforts to personalize therapy for one of the deadliest cancers. Ono’s research bridges high-throughput proteomics and clinical oncology, demonstrating how molecular profiling can directly inform patient stratification. His work stands as a vital contribution to the goal of precision medicine in oncology, offering a data-driven path toward more effective, individualized cancer care.

Research Focus

Key Achievements

1
H-Index
1
Papers
35
Total Citations
35
Avg Citations/Paper
🏆 Most Cited Paper
Survival Prediction for Pancreatic Cancer Patients Receiving Gemcitabine Treatment
35 citations · 2010
📈 Most Prolific Year: 2010 (1 Papers)
🤝 Key Collaborators: 17
🏛 Institutions: National Cancer Research Institute

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago